Tuesday, Oct. 28, 2025 at 4:30 p.m. Eastern TimeFREMONT, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, announced today that it will host a conference call and webcast on Tuesday, Oct. 28, 2025 at 4:30 p.m. Eastern Time to discuss its third quarter 2025 financial results for the period ended Sept. 30, 2025. The live webcast can be accessed on the Enphase Energ ...

The Company’s core treasury asset, BNB token, is on a historic run, hitting an all time high of $1,236.74 and a market cap of over $170 Billion$BNC is the world’s largest BNB Treasury Company, and is listed on NASDAQ Louisville, CO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- CEA Industries Inc. (Nasdaq: BNC) , (“BNC” or the “Company”), today announced that it now holds a total of 480,000 BNB tokens, with an average acquisition cost of $860 per BNB, representing a total invested amount of approximately $412.8 million ...

BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that new data will be presented supporting the combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor and ruzasvir, an NS5A inhibitor, as a potential best-in-class regimen for the treatment of hepatitis C (HCV) infection at Th ...

$25.2 million in first closing, $1.2 million in second closing and $2.8 million in third and final closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term preferred investment optionsHINGHAM, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) (“Microbot” or the “Company”), today announced the third and final closing of its previously announced exercise of certain outstanding preferred investment opti ...

VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- SHARC International Systems Inc. (CSE: SHRC) (FSE: IWIA) (OTCQB: INTWF) ("SHARC Energy" or the “Company”), the pioneer of Wastewater Energy Transfer (“WET”), co-hosted a standing-room-only panel discussion during Climate Week NYC. The panel, Reimagining Building Development: AI & Disruptive Technologies, was hosted at the HIGHMARK | Building Efficiency event space and brought together voices from government, labor, and innovation to explore how ...

TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Appointed Ms. Linda Miller as Senior Scientific AdvisorOver 20 Years of Experience in Advanced Materials, Battery Technology Commercialization, and Global Supply Chain Leadership Experience Securing Major Supply Agreements with Leading Consumer Electronics OEM Will Guide Commercialization into Specialty Electronics Market and Support Operations at New Battery Components Manufacturing Facility NEO Battery Materials Ltd. (“NEO” or the “Company”) (TSXV: NBM) (OTC: NB ...

Core Viewpoint - Extendicare Inc. is set to release its financial results for Q3 2025 on November 11, 2025, followed by a conference call on November 12, 2025, to discuss the results [1]. Company Overview - Extendicare is a leading provider of care and services for seniors in Canada, operating under various brands including Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Network [4]. - The company operates a network of 99 long-term care homes, with 59 owned and 40 under management contracts [4]. - Extendicare delivers approximately 11.5 million hours of home health care services annually and provides group purchasing services for about 149,300 beds across Canada [4]. - The company employs around 28,000 qualified and dedicated team members focused on delivering high-quality care [4].

Core Viewpoint - Ascentage Pharma Group International is actively participating in several investor conferences in October 2025, highlighting its ongoing commitment to engage with investors and stakeholders in the biopharmaceutical sector [1][7]. Company Overview - Ascentage Pharma is a global, commercial stage, integrated biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for unmet medical needs in cancer [2][5]. - The company has developed a robust pipeline of innovative drug products, including inhibitors targeting key apoptotic pathway proteins and next-generation kinase inhibitors [2]. Product Portfolio - The first approved product, Olverembatinib, is a third-generation BCR-ABL1 inhibitor for chronic myelogenous leukemia (CML) patients with specific mutations and is included in the China National Reimbursement Drug List [3]. - The second approved product, Lisaftoclax, is a Bcl-2 inhibitor for various hematologic malignancies, with multiple global registrational Phase III trials currently underway [4]. Research and Development - Ascentage Pharma has established a strong R&D capability and has built a portfolio of global intellectual property rights [5]. - The company has formed partnerships with leading biotechnology and pharmaceutical companies, including Takeda, AstraZeneca, Merck, and Pfizer, as well as collaborations with prominent research institutions [5].

Hong Kong, China, Oct. 07, 2025 (GLOBE NEWSWIRE) -- The Ontic platform, a blockchain and digital asset platform tailored for large Chinese state-owned enterprises operating overseas, announced it will officially launch at 10:00 AM on October 10, 2025 (HKT, UTC+8). This forward-looking Real-World Asset (RWA) digitalization platform, leveraging blockchain technology, integrates technical innovation, compliance assurance, and ecosystem development. It aims to meet the digitalization and compliant circulation n ...

SOMERSET, N.J., Oct. 07, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (“CareCloud” or the “Company”) (Nasdaq: CCLD, CCLDO), a leader in healthcare technology and generative AI solutions for medical practices and health systems nationwide, announced today that its Board of Directors (the “Board”) has declared monthly cash dividends for its 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock (“Series A Preferred Stock”) and its 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock (“Series B P ...